Emollient bath and shower products, soya-bean oil-containing
Brand names: Balneum
These are soya-bean oil-containing emollient bath and shower products used to moisturise dry, scaly skin conditions such as eczema.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
The dispersed soya-bean oil deposits a lipid film on the skin during bathing, reducing water loss and helping restore the skin barrier.
Prescribing in practice
- Although marketed as not containing paraffin, any emollient residue on fabrics can contribute to a fire risk, so the standard advice to avoid naked flames and smoking should still be given.
- Bath and shower surfaces become slippery, so non-slip precautions reduce the risk of falls.
- Use as an adjunct to regular leave-on emollients, which remain the mainstay of dry-skin management.
Monitoring
No blood monitoring is required; assess skin response and tolerability, including any contact irritation, at review.
Counselling the patient
- Avoid smoking and naked flames near skin, clothing or bedding that has been in contact with the product.
- Be careful of slippery surfaces when bathing or showering.
- Apply a leave-on emollient regularly between baths for best effect.
Evidence & guidelines
Emollient bath products are long-used adjuncts in dry-skin care, while trial evidence such as BATHE has questioned added benefit of bath additives over leave-on emollients.
Reference: NICE CKS Eczema; BAD; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD